These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 11694783)

  • 1. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
    Baselga J
    Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line Herceptin monotherapy in metastatic breast cancer.
    Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ
    Oncology; 2001; 61 Suppl 2():37-42. PubMed ID: 11694786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Herceptin in primary breast cancer: views from North America and Europe.
    Leyland-Jones B; Smith I
    Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 6. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials of Herceptin(trastuzumab).
    Baselga J
    Eur J Cancer; 2001 Jan; 37 Suppl 1():S18-24. PubMed ID: 11167087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of HER2 in breast cancer.
    Piccart M; Lohrisch C; Di Leo A; Larsimont D
    Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Breast cancer: HER2 changes one's cards on the table].
    Lopez M
    Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.
    Smith IE
    Anticancer Drugs; 2001 Dec; 12 Suppl 4():S3-10. PubMed ID: 11989525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What can we learn from Herceptin trials in metastatic breast cancer?
    Bell R
    Oncology; 2002; 63 Suppl 1():39-46. PubMed ID: 12422054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ongoing trials with trastuzumab in metastatic breast cancer.
    Bell R
    Ann Oncol; 2001; 12 Suppl 1():S69-73. PubMed ID: 11521725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].
    Ficorella C
    Tumori; 2001; 87(1 Suppl 2):S10-8. PubMed ID: 11357872
    [No Abstract]   [Full Text] [Related]  

  • 14. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer.
    Cook-Bruns N
    Oncology; 2001; 61 Suppl 2():58-66. PubMed ID: 11694789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximizing the response to Herceptin therapy through optimal use and patient selection.
    Leyland-Jones B
    Anticancer Drugs; 2001 Dec; 12 Suppl 4():S11-7. PubMed ID: 11989522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
    Perez EA; Reinholz MM; Hillman DW; Tenner KS; Schroeder MJ; Davidson NE; Martino S; Sledge GW; Harris LN; Gralow JR; Dueck AC; Ketterling RP; Ingle JN; Lingle WL; Kaufman PA; Visscher DW; Jenkins RB
    J Clin Oncol; 2010 Oct; 28(28):4307-15. PubMed ID: 20697084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose scheduling--Herceptin.
    Leyland-Jones B
    Oncology; 2001; 61 Suppl 2():31-6. PubMed ID: 11694785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New combinations with Herceptin in metastatic breast cancer.
    Winer EP; Burstein HJ
    Oncology; 2001; 61 Suppl 2():50-7. PubMed ID: 11694788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs].
    Galligioni E
    Tumori; 2001; 87(1 Suppl 2):S1-9. PubMed ID: 11357871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 39.